2. Search Result
Search Result
Results for "

Selective inhibitor

" in MedChemExpress (MCE) Product Catalog:

6642

Inhibitors & Agonists

6

Screening Libraries

21

Fluorescent Dye

19

Biochemical Assay Reagents

183

Peptides

1

MCE Kits

9

Inhibitory Antibodies

243

Natural
Products

309

Isotope-Labeled Compounds

55

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149597
    Lysyl hydroxylase 2-IN-1

    		Monoamine Oxidase Cancer
    Lysyl hydroxylase 2-IN-1 (compound 12) is a selective lysyl hydroxylase 2 (LH2) Inhibitor with an IC50 of ~300 nM. Lysyl hydroxylase 2-IN-1 demonstrates selectivity for LH2 over LH1 and LH3 .
    Lysyl hydroxylase 2-IN-1
  • HY-149725
    proMMP-9 selective inhibitor-1

    		MMP Neurological Disease
    proMMP-9 selective inhibitor-1 (compound 33) is a highly potent and selective inhibitor of proMMP-9 activation .
    proMMP-9 selective inhibitor-1
  • HY-161294
    COX-2-IN-41

    		COX Cancer
    COX-2-IN-41 (compound 5e) is a selective inhibitor of COX-2 (IC50=1.74 μM). Compared with COX-1, the selectivity IC50 (COX-1)/IC50(COX-2) =16.32 .
    COX-2-IN-41
  • HY-101776
    Desmethyl-VS-5584

    Desmethyl-SB2343

    		 mTOR PI3K Cancer
    Desmethyl-VS-5584 is a dimethyl analog of VS-5584 which is an potent and selective mTOR/PI3K dual inhibitor with pyrido [2,3-d] pyrimidine structure .
    Desmethyl-VS-5584
  • HY-133850
    10-DEBC

    		Pim Cancer
    10-DEBC is a selective Akt inhibitor. 10-DEBC shows strong inhibitory activity against Moloney murine leukemia virus (Pim) kinase-1 (IC50=1.28 μM) .
    10-DEBC
  • HY-159568
    hCAIX-IN-22

    		Carbonic Anhydrase Cancer
    hCAIX-IN-22 is a highly selective inhibitor of human carbonic anhydrase (hCA) isoform XII (Ki=9.7 nM) with anticancer activity .
    hCAIX-IN-22
  • HY-151896
    HDAC6-IN-14

    		HDAC Cancer
    HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC50 of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .
    HDAC6-IN-14
  • HY-161066
    KRAS G13D-IN-1

    		Ras Cancer
    KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRAS G13D (IC50: 0.41 nM). The selectivity for KRAS G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades .
    KRAS G13D-IN-1
  • HY-12900
    RB-005

    		SphK Inflammation/Immunology Cancer
    RB-005 is a selective inhibitor of sphingosine kinase 1 (SK1) (IC50=3.6 µM), with weaker inhibition of another isoenzyme, SK2. The selective inhibition of RB-005 helps to distinguish the biological functions and roles of SK1 and SK2, which can be used in the study of inflammatory diseases and cancer .
    RB-005
  • HY-123130
    ABT-770

    		MMP Cancer
    ABT-770 (compound 11) is a highly selective and orally active MMP inhibitor, demonstrating over 1000-fold selectivity for MMP-2 (IC50=4 nM) compared to MMP-1 (IC50=4600 nM). ABT-770 can be utilized in studies related to tumor growth, invasion, and metastasis .
    ABT-770
  • HY-143258
    CDK4/6-IN-8

    		CDK Cancer
    CDK4/6-IN-8 (Compound 7p) is a selective CDK4 and CDK6 inhibitor with IC50 values of 5.01 nM and 3.97 nM, respectively .
    CDK4/6-IN-8
  • HY-14197
    Clorgyline

    M&B 9302

    		 Monoamine Oxidase Neurological Disease
    Clorgyline (M&B 9302) is an orally active, blood-brain barrier permeable and selective monoamine oxidase A (MAO-A) inhibitor. Clorgyline's selective inhibition of MAO-A leads to reduced metabolism of neurotransmitters such as serotonin (5-hydroxytryptamine), which accumulates in the brain. Clorgyline can be used in the study of depression and neurodegenerative diseases .
    Clorgyline
  • HY-147216
    AXKO-0046
    2 Publications Verification

    		 Lactate Dehydrogenase Cancer
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism .
    AXKO-0046
  • HY-B1287
    Citalopram hydrobromide
    5+ Cited Publications

    (±)-Citalopram hydrobromide; Lu 10-171

    		 Serotonin Transporter Autophagy Neurological Disease Cancer
    Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect .
    Citalopram hydrobromide
  • HY-144031S
    Tyk2-IN-8

    		Isotope-Labeled Compounds JAK Inflammation/Immunology
    Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].
    Tyk2-IN-8
  • HY-77493
    (rel)-Tivantinib

    (rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198

    		 Others Cancer
    (rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .
    (rel)-Tivantinib
  • HY-120290
    PU141

    		Histone Acetyltransferase Cancer
    PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
    PU141
  • HY-162671
    BuChE-IN-12

    		Cholinesterase (ChE) Neurological Disease
    BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease .
    BuChE-IN-12
  • HY-148060
    JAK-IN-21

    		JAK Cancer
    JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .
    JAK-IN-21
  • HY-50687
    (3S,4S)-Tivantinib

    (3S,4S)-ARQ 197; ARQ 198

    		 Others Cancer
    (3S,4S)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (3S,4S)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .
    (3S,4S)-Tivantinib
  • HY-133747
    JAK3-IN-9

    		JAK Inflammation/Immunology
    JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM. JAK3-IN-9 is highly selective to the JAK3 signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research .
    JAK3-IN-9
  • HY-69172
    RS-25344

    		Phosphodiesterase (PDE) Cardiovascular Disease Neurological Disease Inflammation/Immunology
    RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4). RS-25344 increases intracellular cAMP (cyclic adenosine phosphate) concentration by inhibiting PDE4 activity. RS-25344 can be used in the study of inflammation, immune diseases, neurodegenerative diseases and cardiovascular diseases .
    RS-25344
  • HY-P10280
    ATR kinase substrate peptide

    		ATM/ATR Cancer
    ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (Ki=6 nM). ATR kinase substrate peptide inhibits ATR activity by competing with ATR kinase ATP-binding sites to block ATR mediated signaling. ATR kinase substrate peptide can be used to study the role of ATR kinase in DNA damage response .
    ATR kinase substrate peptide
  • HY-158102
    ORIC-944

    		Others Cancer
    ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.
    ORIC-944
  • HY-162173
    WYZ90

    		COX Inflammation/Immunology
    WYZ90 ((compound 6a) is a potent and selective COX-2 inhibitor with IC50 values of 75, 5734, 19940 nM for COX-2, COX-1 and DPPH, respectively. WYZ90 shows antioxidant and analgesic activity .
    WYZ90
  • HY-18969
    LDC3140

    		CDK Cancer
    LDC3140 is a selective CDK7 inhibitor (IC50<5 nM). By inhibiting the activity of CDK7, LDC3140 affects the regulation of the cell cycle, leading to cell cycle arrest and thus inhibiting the proliferation of tumor cells. LDC3140 can be used in the research of cancer treatment .
    LDC3140
  • HY-136679
    TD114-2

    		GSK-3 Neurological Disease Metabolic Disease
    TD114-2 (cmpound 29) is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β) (IC50=48 nM). TD114-2 is associated with the hydrogen bond formation of arginine 141 (ARG141) specific to GSK-3β, an amino acid that is often a negatively charged residue in other kinases, which determines the high selectivity of GSK-3β. TD114-2 can be used in the study of diabetes, neurodegenerative diseases and other diseases associated with GSK-3β .
    TD114-2
  • HY-163771
    Pyruvate Carboxylase-IN-5

    		Others Metabolic Disease
    Pyruvate Carboxylase-IN-5 (compound 6m) is a pyruvate carboxylase inhibitor with high selectivity and permeability. Pyruvate carboxylase is a mitochondrial enzyme that catalyzes the carboxylation of pyruvate to oxaloacetate, a process that plays an important role in maintaining steady-state levels of Krebs cycle intermediates, which are precursors for the synthesis of biomacromolecules such as amino acids, fatty acids, and glucose .
    Pyruvate Carboxylase-IN-5
  • HY-158763
    MPI8

    TG0205221

    		 SARS-CoV Cathepsin Virus Protease Infection
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19 .
    MPI8
  • HY-158102A
    ORIC-944 TFA

    		Others Cancer
    ORIC-944 TFA is the TFA salt form of ORIC (HY-158102). ORIC-944 TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .
    ORIC-944 TFA
  • HY-164145
    CDD-1653

    		TGF-β Receptor Others Cancer
    CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway .
    CDD-1653
  • HY-144614
    JH-XVII-10

    		DYRK Apoptosis Neurological Disease Cancer
    JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC50s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .
    JH-XVII-10
  • HY-147695
    c-Met-IN-12

    		c-Met/HGFR Cancer
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .
    c-Met-IN-12
  • HY-163783
    CSNK2-IN-1

    		Casein Kinase Infection
    CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC50 of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development .
    CSNK2-IN-1
  • HY-164151
    ERK-IN-8

    		ERK Cancer
    ERK-IN-8 (compound I-1) is an aniline pyrimidine derivative that acts as an ERK inhibitor. ERK-IN-8 has a strong inhibitory effect on ERK2 in vitro (IC50≤50 nM). ERK-IN-8 can be used in cancer research .
    ERK-IN-8
  • HY-155154
    PRMT4-IN-2

    		Others Cancer
    PRMT4-IN-2 (compound 55) is a pan-inhibitor of protein arginine methyltransferase (PRMT) with IC50s of 92 nM (PRMT4), 436 nM (PRMT6), 460 nM (PRMT1), 823 nM ( PRMT8), 1.386 μM (PRMT3) .
    PRMT4-IN-2
  • HY-155154A
    PRMT4-IN-3

    		Histone Methyltransferase Cancer
    PRMT4-IN-3 (compound 56) is a potent inhibitor of class I protein arginine methyltransferase (PRMT), targeting PRMT4 (IC50: 37 nM) and PRMT4 (IC50: 253 nM) .
    PRMT4-IN-3
  • HY-157302
    c-Met-IN-21

    		c-Met/HGFR Cancer
    c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC50 value of 0.45? nM, and shows anti-tumor efficacy in vivo .
    c-Met-IN-21
  • HY-13506G
    M344 (GMP)

    D 237 (GMP); MS 344 (GMP)

    		 HDAC Cancer
    M344 (GMP) (D 237) (GMP) is the GMP level of M344 (HY-13506). GMP level of small molecules can be used as auxiliary reagents in cell therapy. M344 is a kind of histone acetylation enzyme inhibitor .
    M344 (GMP)
  • HY-120944
    BAY-7598

    		MMP Inflammation/Immunology
    BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively .
    BAY-7598
  • HY-156793
    hRIO2 kinase ligand-1

    		Others Others
    hRIO2 kinase ligand-1 (com 9) is a ligand of hRIO2 kinase, with a Kd value of 520 nM .
    hRIO2 kinase ligand-1
  • HY-112304
    NCD38 TFA

    		Histone Demethylase Others
    NCD38 TFA is a LSD1-selective inhibitor .
    NCD38 TFA
  • HY-157131
    TRPV2-selective blocker 1

    		TRP Channel Neurological Disease
    TRPV2-selective blocker 1 (compound IV2-1) is a selective TRPV2 channel blocker with an IC50 of 6.3 μM. TRPV2-selective blocker 1 does not affect TRPV1, TRPV3 or TRPV4 channels. TRPV2-selective blocker 1 also inhibits TRPV2-mediated Ca 2+ influx in macrophages, and inhibits macrophage phagocytosis .
    TRPV2-selective blocker 1
  • HY-112910
    Grp94 Inhibitor-1
    2 Publications Verification

    		 HSP Inflammation/Immunology Cancer
    Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α .
    Grp94 Inhibitor-1
  • HY-12055
    BIX02188
    3 Publications Verification

    		 MEK ERK Cancer
    BIX02188 is a potent MEK5-selective inhibitor with an IC50 of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC50 of 810 nM.
    BIX02188
  • HY-100263
    Metofenazate

    Methophenazine

    		 Autophagy Calmodulin Neurological Disease
    Metofenazate is a selective calmodulin inhibitor.
    Metofenazate
  • HY-119935
    JAK3 covalent inhibitor-1

    		JAK Inflammation/Immunology
    JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs .
    JAK3 covalent inhibitor-1
  • HY-144991
    Aurora kinase inhibitor-8

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases.
    Aurora kinase inhibitor-8
  • HY-13227
    SD-208
    5+ Cited Publications

    		 TGF-β Receptor Cancer
    SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
    SD-208
  • HY-150041
    TL4830031

    		TAM Receptor Cancer
    TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent Axl inhibitor with an IC50 value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research .
    TL4830031

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: